Pressure BioScience (OTCQB: PBIO) today announced the
appointment of personal care industry leader Jim Morrison to serve as the new
CEO of the rebranded public company, with intended corporation name of Availa
Bio, upon completion of the merger with Cannaworx, SkinScience Labs and
Pressure BioSciences. Morrison’s career includes numerous leadership positions
in the personal care industry, most notably as President of L’Oréal where he
oversaw growth that averaged more than 20% year-over-year. In addition,
Morrison engineered the acquisitions of Redken and Matrix and led the company
during a period of unprecedented growth. “Jim is one of the preeminent beauty
and personal care brand builders in the world today. Following his
accomplishments as CEO in making Graham Webb one of the most successful
startups of the 90s, Jim led L’Oréal for almost a decade, delivering
significant growth organically and through acquisitions,” Cannaworx President
Dr. Bobby Ghalili said in the news release. “He also served as President and
Chairman of the American Beauty Association from 1998 to 2004. Hands down, Jim
is virtually unmatched in the experience and credibility we sought to lead our
revolutionary products and growth vision for Availa Bio.”
To view the full press release, visit http://ibn.fm/WR7ek
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure-cycling
technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil and plant biology, forensics and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology)
to allow entry into the biopharma contract services sector, and (2) the use of
its recently patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality,
homogenized, extended shelf-life or room-temperature, stable, low-acid liquid
foods that cannot be effectively preserved using existing nonthermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
